Kymera Therapeutics vs Arcus Biosciences
KYMR and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYMR and RCUS compare
Kymera Therapeutics is the larger company, worth 4.5 times as much as Arcus Biosciences ($10.5B against $2.3B).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −55.3% for Arcus Biosciences).
Kymera Therapeutics keeps more of each dollar of sales as profit, with a net margin of −342% compared with −393% at Arcus Biosciences.
Kymera Therapeutics scores higher on the StockData Score (9 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYMR | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $10.5B | $2.3B |
| Share price | $126.63 | $18.19 |
| Change, 1 year | 111% | −10.3% |
| Change, 5 years | 95.0% | −47.9% |
| Beta (5Y) | 1.97 | 1.43 |
| Employees | 238 | 601 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 103× | 19.8× (better) |
| P/B | 6.5× | 5.0× (better) |
| FCF yield | −2.7% (better) | −20.5% |
| Fair value | $38.85 | $7.49 |
| Margin of safety | −226% | −143% (better) |
| Growth | ||
| Revenue growth (TTM) | 134% (better) | −55.3% |
| Revenue growth, 5Y average | 2.9% | 25.9% (better) |
| Profitability | ||
| Gross margin | 0.00% | – |
| Operating margin | −396% (better) | −415% |
| Net margin | −342% (better) | −393% |
| FCF margin | −283% (better) | −406% |
| Return on equity | −27.3% (better) | −90.8% |
| Return on invested capital | −59.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −44.2× |
| Current ratio | 11.13 (better) | 3.82 |
| Altman Z-score | 40.23 (better) | −0.45 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.4% |
| Shareholder yield | 0.00% (better) | −12.4% |
| Ownership | ||
| Held by institutions | 117% | 96.3% |
| Held by insiders | 39.4% | 31.7% |
| Insider net buying, 12 months | −$297M | −$11.4M (better) |
| Short interest, % of float | 19.7% | 15.1% |
Go deeper
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.